Description: Cambridge Cognition Holdings plc and its subsidiaries develop and commercialize computerized neuropsychological tests for sale, principally in the United Kingdom, the United States and Europe. The Company's segments include Pharmaceutical Clinical Trials, Academic Research and Healthcare Technology. The Pharmaceutical Clinical Trials segment includes products and services for use in regulated pharmaceutical clinical trials. The Academic Research segment includes cognitive test products for researchers working in a non-regulated environment, typically in academia. The Healthcare Technology segment includes medical software for use in healthcare delivery settings. The Company is a provider of validated touchscreen cognitive assessments for clinical trials. The Company's product, CANTAB Mobile is a Class II medical device, used to identify patients exhibiting the early signs of Alzheimer's disease. It also offers Cantab Insight for dementia assessment in secondary care.
Home Page: www.cambridgecognition.com
COG Technical Analysis
Tunbridge Court
Cambridge,
CB25 9TU
United Kingdom
Phone:
44 1223 810 700
Officers
| Name | Title |
|---|---|
| Dr. Matthew Stork | CEO & Director |
| Mr. John Hammond | Co-Founder |
| Mr. Stephen Daniel Symonds | CFO & Exec. Director |
| Mr. Nick Taptiklis | Head of Technology Strategy |
| Ms. Francesca Cormack Ph.D. | Chief Scientist |
| Mr. Simon Merritt | Marketing and Communications Director |
| Dr. Lisa Elizabeth Nolan Ph.D. | VP Bus. Devel. |
| Ms. Nicky Ackerley | Global HR Director |
| Prof. Trevor Robbins | Sr. Consultant |
| Prof. Barbara Sahakian FMedSci, FBPsS | Sr. Consultant |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 238.0952 |
|---|---|
| Trailing PE: | 123.445 |
| Price-to-Book MRQ: | 200.0272 |
| Price-to-Sales TTM: | 3.2603 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 60 |